Technology Appraisal Committee Meeting (Committee B)

**10 Spring Gardens**

**London**

**SW1A 2BU**

# Minutes: Confirmed

## Date and Time: Tuesday 11 February 2020, 10am to 4pm

### Present:

1. Dr Amanda Adler (Chair) Present for all notes
2. Dr Sanjeev Patel (Vice Chair) Present for all notes
3. Dr Laura Bojke Present for all notes
4. Professor John Cairns Present for all notes
5. Mr Mark Chapman Present for all notes
6. Mr Gareth Hooper Present for all notes
7. Dr Megan John Present for all notes
8. Dr Sanjay Kinra Present for all notes
9. Dr Nicholas Latimer Present for all notes
10. Dr Veline L'Esperance Present for all notes
11. Prof Allyson Pollock Present for all notes
12. Dr Stephen Smith Present for all notes
13. Professor Nicky Welton Present for all notes
14. Dr Ed Wilson Present for all notes
15. Professor Sarah Wild Present for all notes
16. Dr Stuart Williams Present for all notes
17. Mr Tony Wootton Present for all notes

### In attendance:

* Helen Knight, Programme Director, NICE, Present for all notes
* Nicole Elliott, Associate Director, NICE, Present for notes 1 to 23
* Melinda Goodall, Associate Director, NICE, Present for notes 24 to 31
* Joanne Ekeledo, Project Manager, NICE, Present for all notes
* Jeremy Powell, Project Manager, NICE, Present for all notes
* Shelly Patel, Technical Analyst, NICE, Present for notes 1 to 23
* Eleanor Donegan, Technical Adviser, NICE, Present for notes 1 to 23
* Iordanis Sidiropoulos, Technical Analyst, NICE, Present for notes 24 to 31
* Carl Prescott, Technical Adviser, NICE, Present for notes 24 to 31
* Professor Jo Lord, Southampton Health Technology Assessments Centre, Evidence Review Group, Present for notes 1 to 21
* Dr Jo Picot, Southampton Health Technology Assessments Centre, Evidence Review Group, Present for notes 1 to 21
* Professor Ian Pavord, Clinical Expert, Professor of Respiratory Medicine, Department Lead and Principal Investigator, University of Oxford & Oxford University Hospitals NHS Foundation Trust, Present for notes 10 to 19
* Ms Lottie Renwick, Patient Expert, Policy Analyst, Asthma UK, Present for notes 10 to 19
* Dr Nicola Ridgway, Patient Expert, Present for notes 10 to 19
* Professor Peter Clark, Chair of NHS England Chemotherapy Clinical Reference Group and National Clinical Lead for CDF, Present for notes 24 to 31

### Non-public attendees:

* Helen Barnett, Medical Editor, NICE, Present for all notes
* Yelan Guo, Technical Advisor, NICE, Present for all notes
* Heidi Livingstone, PIP Advisor, NICE, Present for all notes
* Edgar Masanga, RIA, NICE, Present for all notes

## Notes

### Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure [ID3754], dupilumab for treating severe asthma [ID1213] and avelumab with axitinib for untreated advanced or metastatic renal cell carcinoma [ID1547].
2. The Chair welcomed Dr Ed Wilson to his first meeting as a member of the Appraisal Committee.
3. The Chair informed the Committee of the non-public observers at this meeting: Helen Barnet, Yelan Guo, Heidi Livingstone and Edgar Masanga.
4. Apologies were received from Dr Susan Faulds, Dr Mark Glover and Mr Peter Wheatley Price.

### Any other Business

1. The Committee were given an update on the progress of other appraisals discussed at previous meetings.

## Appraisal of avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure [ID3754]

### Part 2 – Closed session

1. The Chair asked all Committee members to declare any relevant interests.  
   1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Laura Bojke, Professor John Cairns, Mr Mark Chapman, Mr Gareth Hooper, Dr Megan John, Dr Sanjay Kinra, Dr Nicholas Latimer, Dr Veline L'Esperance, Professor Allyson Pollock, Dr Stephen Smith, Professor Nicky Welton, Dr Ed Wilson, Professor Sarah Wild, Dr Stuart Williams and Mr Tony Wootton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure [ID3754].
2. The Chair asked all NICE Staff to declare any relevant interests.
   1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure [ID3754].
3. The Chair explained that the Committee had considered the appraisal of avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520] at their meeting on 26 September 2019. The Committee had considered the clinical evidence for both drugs and the Assessment Group’s economic analysis but had been unable to reach a final decision on avatrombopag because the price had not yet been approved. Avatrombopag now has an approved price and the Committee were therefore asked whether they wished to extend their recommendations to cover avatrombopag on the basis of that price.
4. The Committee instructed the technical team to prepare the Final Appraisal Document (FAD) in line with their decisions.

**Notes from the last meeting**

1. The minutes of the meetings held on 26 November 2019 and 15 January 2020 were approved.

## Appraisal of dupilumab for treating severe asthma [ID1213]

**Part 1 – Open session**

1. The Chair welcomed the invited experts: Professor Jo Lord, Dr Jo Picot, Professor Ian Pavord, Ms Lottie Renwick and Dr Nicola Ridgway to the meeting and they introduced themselves to the Committee.
2. The Chair welcomed company representatives from Sanofi to the meeting.
3. The Chair asked all Committee members to declare any relevant interests.
   1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Laura Bojke, Professor John

Cairns, Mr Mark Chapman, Mr Gareth Hooper, Dr Megan John, Dr Sanjay Kinra, Dr Nicholas Latimer, Dr Veline L'Esperance, Professor Allyson Pollock, Dr Stephen Smith, Professor Nicky Welton, Dr Ed Wilson, Professor Sarah Wild, Dr Stuart Williams and Mr Tony Wootton.

* 1. Mr Peter Wheatley-Price declared before the meeting that he had a

personal specific financial interest as he owns shares in

GlaxoSmithKline, one of the comparator manufacturers.

* + 1. It was agreed that Mr Wheatley-Price would not participate in this appraisal.

1. The Chair asked all NICE Staff to declare any relevant interests.
   1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of dupilumab for treating severe asthma [ID1213].
2. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
   1. Professor Jo Lord, Dr Jo Picot, Ms Lottie Renwick and Dr Nicola Ridgway declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of dupilumab for treating severe asthma [ID1213].
   2. Professor Ian Pavord declared personal financial interests as he has received honararia for speaking at meetings from AstraZeneca, Novartis, Teva, Sanofi/Regeneron and GSK; payments for organising educational events from AstraZeneca, GSK, Sanofi/Regeneron and Teva; honoraria for attending advisory panels with Sanofi/Regeneron, AstraZeneca, BGSK, Novartis, Teva; payments to support FDA approval meetings from GSK; sponsorship to attend international scientific meetings from GSK, AstraZeneca and Teva.
      1. It was agreed that this declaration would not prevent Professor Pavord from participating in this section of the meeting.
3. The Chair introduced the lead team, Dr Veline L’Esperance, Mr Tony Wootton and Mr Gareth Hooper who gave presentations on the clinical effectiveness and cost effectiveness of dupilumab for treating severe asthma [ID1213].
4. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
5. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
6. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

### Part 2 – Closed session

1. Discussion on confidential information continued. This information was supplied by the company.
2. The Chair then thanked the Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.
3. The Committee continued to discuss the clinical and cost effectiveness of dupilumab for treating severe asthma [ID1213].
   1. The committee decision was based on consensus.
4. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document (FAD) in line with their decisions.

## Appraisal of avelumab with axitinib for untreated advanced or metastatic renal cell carcinoma [ID1547]

### Part 2 – Closed session

1. The Chair welcomed the invited expert: Professor Peter Clark to the meeting and he introduced himself to the Committee.
2. The Chair asked all Committee members to declare any relevant interests.
   1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Laura Bojke, Professor John Cairns, Mr Mark Chapman, Mr Gareth Hooper, Dr Megan John, Dr Sanjay Kinra, Dr Nicholas Latimer, Dr Veline L'Esperance, Professor Allyson Pollock, Dr Stephen Smith, Professor Nicky Welton, Dr Ed Wilson, Professor Sarah Wild, Dr Stuart Williams and Mr Tony Wootton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of avelumab with axitinib for untreated advanced or metastatic renal cell carcinoma [ID1547].
3. The Chair asked all NICE Staff to declare any relevant interests.
   1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of avelumab with axitinib for untreated advanced or metastatic renal cell carcinoma [ID1547].
4. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
   1. Professor Clark declared that he knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of avelumab with axitinib for untreated advanced or metastatic renal cell carcinoma [ID1547].
5. The Chair presented the additional information submitted by the company since the previous Committee meeting on 15 January.
6. The Committee continued to discuss the clinical and cost effectiveness of avelumab with axitinib for untreated advanced or metastatic renal cell carcinoma [ID1547].
   1. A vote was taken. The options were:

Option 1: to recommend avelumab for use in the Cancer Drugs Fund

Option 2: not to recommend avelumab for use in the Cancer Drugs Fund

The Committee voted for Option 1.

1. The Committee instructed the technical team to prepare Final Appraisal Document (FAD) in line with their decisions.

## Date, time and venue of next meeting

1. Thursday 12 March 2020 at Avonmouth House, 6 Avonmouth Street, London SE1 6NX.